Deleted Journal, Journal Year: 2025, Volume and Issue: 33(1), P. 200935 - 200935
Published: Feb. 3, 2025
Language: Английский
Cancers, Journal Year: 2025, Volume and Issue: 17(5), P. 809 - 809
Published: Feb. 26, 2025
Cancers represent a significant global health burden, affecting millions of individuals each year [...].
Language: Английский
Citations
0
Targets, Journal Year: 2025, Volume and Issue: 3(1), P. 8 - 8
Published: March 3, 2025
Proteases play a pivotal role in cancer progression, facilitating processes such as extracellular matrix degradation, angiogenesis, and metastasis. Consequently, protease inhibitors have emerged promising therapeutic agents oncology. This review provides comprehensive overview of the mechanisms by which modulate biology, categorizing their target classes, including metalloproteinases, cysteine proteases, serine proteases. We discuss potential both synthetic natural inhibitors, highlighting applications preclinical clinical settings. Furthermore, challenges specificity, toxicity, resistance are addressed, alongside strategies to overcome these limitations through innovative drug designs combination therapies. The future treatment lies precision medicine, leveraging proteomic profiling tailor therapies individual tumors. underscores importance ongoing research development novel approaches harness effectively for management.
Language: Английский
Citations
0
World Journal of Surgical Oncology, Journal Year: 2025, Volume and Issue: 23(1)
Published: March 19, 2025
Gastric adenocarcinoma (GAC) remains a significant global public health challenge, characterized by high incidence and mortality rates. Progress in tumor immunology has introduced immune checkpoint inhibitors (ICIs) targeting the programmed cell death-1 (PD-1)/programmed death-ligand 1 (PD-L1) cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) pathways, demonstrating substantial potential GAC therapy. Clinical research indicates that ICIs, particularly when combined with chemotherapy or targeted therapies, significantly enhance treatment efficacy advanced specific molecular subtypes, including microsatellite instability-high (MSI-H) human epidermal growth factor receptor 2 (HER2)-positive patients. However, immunotherapy is also associated range of immune-related adverse events (irAEs), necessitating effective management strategies to ensure safety maintain patients' quality life. Future studies should focus on identifying new therapeutic targets, optimizing patient selection, developing personalized approaches further improve GAC.
Language: Английский
Citations
0
Experimental Cell Research, Journal Year: 2025, Volume and Issue: unknown, P. 114580 - 114580
Published: April 1, 2025
Language: Английский
Citations
0
PLoS ONE, Journal Year: 2025, Volume and Issue: 20(5), P. e0323699 - e0323699
Published: May 14, 2025
This study focuses on the development and optimization of S11a-0000168202, a novel LIMK1 inhibitor with potential therapeutic applications in gastric cancer. Through scaffold hopping structural modification HIT100844099, S11a-0000168202 demonstrated enhanced binding stability stronger interactions key residues, including GLU-414, ILE-416, HIS-464. Molecular dynamics simulations MMGBSA analyses confirmed compound’s stability, while ADMET evaluation revealed favorable properties such as moderate lipophilicity, good human intestinal absorption, low P-glycoprotein inhibition. Despite promising computational results, lack experimental validation remains limitation. Future studies should focus vitro vivo testing to confirm S11a-0000168202’s efficacy, pharmacokinetics, safety. compound holds significant agent for LIMK1-targeted cancer treatment.
Language: Английский
Citations
0
Deleted Journal, Journal Year: 2025, Volume and Issue: 33(1), P. 200935 - 200935
Published: Feb. 3, 2025
Language: Английский
Citations
0